Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO

J Allergy Clin Immunol. 2019 Apr;143(4):1629-1633.e2. doi: 10.1016/j.jaci.2018.11.032. Epub 2018 Dec 18.

Authors

Nicola A Hanania¹, Bradley E Chipps², Noelle M Griffin³, Bongin Yoo⁴, Ahmar Iqbal⁵, Thomas B Casale⁶

Affiliations

¹ Airways Clinical Research Center, Baylor College of Medicine, Houston, Tex.
² Capital Allergy and Respiratory Disease Center, Sacramento, Calif.
³ Aimmune Therapeutics, Brisbane, Calif.
⁴ Genentech, Inc, South San Francisco, Calif.
⁵ Genentech, Inc, South San Francisco, Calif. Electronic address: iqbal.ahmar@gene.com.
⁶ University of South Florida, Tampa, Fla.

PMID: 30576755
DOI: 10.1016/j.jaci.2018.11.032

No abstract available

Publication types

Letter
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Anti-Asthmatic Agents / therapeutic use*
Asthma / complications
Asthma / drug therapy*
Female
Humans
Male
Middle Aged
Omalizumab / therapeutic use*
Pulmonary Disease, Chronic Obstructive / complications
Pulmonary Disease, Chronic Obstructive / drug therapy*
Treatment Outcome
Young Adult

Substances

Anti-Asthmatic Agents
Omalizumab

Associated data

ClinicalTrials.gov/NCT01922037